Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

Profound Medical Corp.
Next earnings Aug 12, 2026 · consensus $-0.26 EPS, $4.92M rev
Last earnings -0.8% on 2026-05-07
Revenue grew 50.7% YoY; but unprofitable (net margin -264.4%).
Sources: SEC EDGAR (CIK 0001628808, latest 10-Q filed 2026-05-07) · EODHD · as of 6/22/2026, 2:56:05 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
Middling fundamentals offset by an attractive price (~49% below fair value) — worth a look on the value angle.
Profound Medical Corp. shows $16.1M in FY2025 revenue (+50.7% YoY), a -264.4% net margin, and -64.1% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $7.20M | $10.7M | $16.1M |
| Gross profit | $4.31M | $7.04M | $11.4M |
| Operating income | -$28.7M | -$33.1M | -$41.3M |
| Net income | -$28.3M | -$27.8M | -$42.6M |
| Diluted EPS | $1.34 | $1.12 | $1.41 |
| Net margin | -393.4% | -260.4% | -264.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
| 2025-05-16 | Menawat Arun Swarup CEO | Buy | 12.0K @ $4.73 | $56.9K |
| 2025-05-15 | Menawat Arun Swarup CEO | Buy | 10.0K @ $4.33 | $43.3K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.